Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) ExtendedRelease Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
DUBLIN, Oct. 17, 2024 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company......